Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - adenosine 3 mg/ml;  ;   - solution for injection - 6 mg/2ml - active: adenosine 3 mg/ml     excipient: sodium chloride water for injection - therapeutic indications rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine-claris 6 mg/2 ml is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. sensitisation of intra-cavitary electrophysiological investigations.

Canada - English - Health Canada

fresenius kabi canada ltd - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

Canada - English - Health Canada

mylan pharmaceuticals ulc - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

Canada - English - Health Canada

fresenius kabi canada ltd - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

Canada - English - Health Canada

fresenius kabi canada ltd - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

Canada - English - Health Canada

mylan pharmaceuticals ulc - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

United States - English - NLM (National Library of Medicine)

eugia us llc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 60 mg in 20 ml - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine injection [see warnings and precautions (5.7)] pregnancy category c . animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed. it is not known whether adenosine injection is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine injection in nursing infants, the decision to interrupt nursing after administration of adenosine injection or not to administer adenosine injection, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba health first - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation ( see dosage and administration) adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artifi

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية المنار - manar drug store - adenosine 3 mg - 3 mg